IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Role Of Clinical Study In Pharmacy

[1]Rahul Ganesh Wankhade, [2]Dr. Harshal Anwane, [3]Dr. Shivshankar Mhaske, [4]Mayur Gulab Kharat, [5]Karan Dnyanba Gavhane, [6] Rushikesh Gajanan Navale.

[1]Student, [2]Professor, [3]Princilpe, [4] Student, [5]Student, [6]Student.

[1]Pharmacy,

[1]Satyajeet College of Pharmacy, Mehkar, India.

Abstract: Clinical studies play a pivotal role in the field of pharmacy by providing essential data that informs drug development, efficacy, safety, and optimal use in patient populations. These studies are the cornerstone of evidence-based practice, bridging the gap between theoretical pharmacological knowledge and real-world application. Clinical trials are conducted in multiple phases, each designed to address specific aspects of drug evaluation. Phase I focuses on safety, Phase II evaluates efficacy, and Phase III involves large-scale trials to confirm the drug's effectiveness across diverse populations. Phase IV, or post-marketing surveillance, monitors long-term effects and potential adverse reactions after the drug enters the market. Pharmacy professionals play a critical role in designing, conducting, and analysing clinical trials. They ensure proper methodology, patient recruitment, adherence to ethical standards, and accurate data interpretation. Additionally, pharmacists are instrumental in managing pharmacovigilance, ensuring ongoing safety monitoring through adverse event reporting and post-market surveillance.

The integration of clinical studies into pharmacy practice enhances the understanding of drug interactions, patient-specific factors, and the broader impact of medications on public health. Moreover, clinical trials aid in the development of new therapeutic agents, expanding treatment options for patients with unmet medical needs. By advancing personalized medicine, clinical studies contribute significantly to the evolving landscape of pharmaceutical care, guiding therapeutic decision-making and improving health outcomes. The continued collaboration between clinical researchers and pharmacists is crucial for maximizing the benefits of clinical studies in improving patient care and advancing pharmaceutical sciences.

Index Terms **-** Clinical, Clinical study, Clinical Development, Pharmacovigilance, Human trials.

I. INTRODUCTION

A multiphase study carried out on human volunteers by researchers to evaluate a medical treatment or preventative measure is known as a clinical trial. A medication, surgery, medical equipment, or therapy could be the medical treatment being examined. **[5]** A clinical trial is a methodical procedure designed to determine if a medication or medical technology is safe and effective in treating, preventing, or diagnosing a disease or other medical condition. **[7]** To guarantee the best possible outcomes for patients, a clinical pharmacy service (CPS) makes use of the pharmacist's therapeutic experience. **[44]** In the secondary care industry, clinical pharmacy started to take shape in the 1970s and has since developed into a service called pharmaceutical care. **[13]** Phase 0 (micro-dosing studies), Phase 1, Phase 2, Phase 3, and Phase 4 are among the phases that comprise a clinical study. **[10]** The exploratory trial phases are referred to as phases 0 and 2, the non-therapeutic period as phase 1, the therapeutic confirmatory phase as phase 3, and the post-approval or post-marketing monitoring phase as phase 4. Before being given as part of the phase 1 study among healthy individuals, phase 0, also known as the micro-dosing phase, is currently conducted in human volunteers to determine the dose tolerability (pharmacokinetics). Previously, this phase was conducted in animals. The specifics of the phases of clinical trials. **[19]** Clinical research is often divided into two categories: observational and experimental. Experimental research refers to any study in which the investigator

intervenes in a population solely for the goal of evaluation. The RCT is the most common type of experimental clinical research. Observational research does not seek to intervene in the study sample only for exploratory goals. **[30]** A clinical pharmacist can analyze drug-related problems in several contexts, including hospital interdisciplinary teams, nursing homes, and primary care. **[54]**Clinical research is the process of analyzing empirical data (information obtained from nature) in order to answer specific clinical problems. **[30]**

The World Health Organization (WHO) defines pharmacovigilance as the science and activities concerned with the detection, assessment, understanding, and prevention of adverse effects or other potential drug-related problems, notably long-term and short-term harmful effects of medications. **[29]** Clinical research is a critical component of evidence-based medicine, which combines individual clinical experience with the best available external clinical evidence from systematic research to inform medical decisions. Individual clinical expertise covers the clinician's ability, whereas external clinical evidence examines clinically relevant and patient-centered research findings. As a result, clinical research is crucial in addressing the demand for standardized clinical decision-making. **[31]** Clinical trials are the most time-consuming and costly phase of drug discovery. Despite the time and money invested in clinical trials, those that receive FDA approval have a marginal success rate. **[14]** Pharmacovigilance is essential for maintaining public health and safety. It enhances patient care and safety in the use of medications. It helps to analyze the value, danger, and effectiveness of medicines, as well as to guarantee that they are used correctly, more effectively, safely, and rationally. The Pharmacovigilance system provides understanding, education, and clinical training. It also offers and encourages good communication with the public. **[29]** Pharmacovigilance may be defined as the continuous monitoring and evaluation of all adverse events during the medication development process in order to ensure the safety of participants (subjects) and the ongoing assessment of risk and benefit. The clinical trial procedure is governed by certain regulatory criteria (ICH GCP, US FDA guidelines, etc.). Clinical trials provide the evidence required for regulatory approval of safe and effective treatments. With protracted development cycles and ever-increasing expenses of performing clinical trials, both the pharmaceutical sector and regulators are attempting to be much more active in safety reviews. **[42]**

History and background

It is critical to understand the background behind the development of the ICH-GCP guidelines. The concept of a 'good physician' extends back to ancient times, as indicated by the Hippocratic Oath (460 BC). The Food and Drugs Act of 1906 was the first step toward drug regulation in the United States. **[15]** Clinical trials have been documented since 500 BC, when they were described in the Bible. The process progresses from dietary therapy (legumes and lemons) to medications. **[24]** The World Medical Association created the Declaration of Helsinki in 1964, which serves as the foundation for the ethical principles that underpin the current ICH-GCP recommendations. **[15]**

The Bible's "Book of Daniel" records the world's first clinical trial. This clinical trial-like experiment was not undertaken by a doctor. The first clinical trial of a novel therapy was unintentionally conducted by the famed surgeon Ambroise Parè in 1537. **[24]**

Clinical pharmacy services were established in the United Kingdom and the United States of America by the end of the 1960s. While pharmacists have traditionally been thought to be 'behind the glass' administering drugs, they are now regarded as key members of the multidisciplinary care team dealing with complex patient needs. Clinical pharmacists increasingly play an important role in hospitals, trying to prevent prescription errors and harmful drug responses. **[45]** In recent years, the number of clinical trials in both developed and developing countries has increased significantly. From 1990 to 1998, clinical trials in the United States roughly doubled. **[49]**

In 2008, the Board of Regents at the American College of Clinical Pharmacy (ACCP) produced a brief and precise explanation of the idea of Clinical Pharmacy. **[12]** Clinical pharmacy practice in the United States has evolved since its inception in the mid-1960s. This progression gave pharmacists greater powers and duties. **[28]** Recent trials have included patients covering all clinical stages of Alzheimer's disease, including preclinical and prodromal AD populations. **[16]** Current guidance provided by the US Food and Drug Administration (FDA) for clinical trials in AD further includes the use of biomarkers in staging preclinical and prodromal AD and a single primary outcome in trials of prodromal AD, as well as the use of Bayesian statistics and modifiable clinical trial designs. **[2]** Furthermore, combined therapy regimens are actively evaluated in clinical trials. **[35]** A search of clinicaltrials.gov from 2012 (accessed September 2019) for phase 3 interventional clinical studies that are "terminated" or "completed" for Alzheimer's disease yielded all pharmacologic AD trials of all drugs that were recently abandoned. The 2019 yearly evaluation of the

Alzheimer's disease medication development pipeline was also used, as were pertinent PubMed publications from the same time period. All of the offered papers on trial failures are clinical studies. Animal studies are included only when more information about the researched agent is required. **[16]** Clinical research is critical to improving medical practice quality, including medication and device approval. This article refers to trials for this purpose as "registration trials". The Japanese infrastructure for registration trials has improved since the introduction of the Good Clinical Practice standard in 1997, and the contribution of clinical research coordinators (CRCs) to registration trials is now widely recognized as providing practical assistance and quality assurance. **[43]**

1. Objectives of the study:

i. To learn about the clinical study.
ii. Promoting public health and encouraging reporting.
iii. Monitoring safety.
iv. Educating the Public
v. Ensure regulatory compliance.

2. Review of literature

2.1. Jeffrey Cummings at el., He added the drug development continues robustly at all phases despite setbacks in several programs in the recent past. Continuing unmet needs require a commitment to growing and accelerating the pipeline. (2)

2.2. Kimberly A. Redic at el., He studies the pilot study showed potential roles for pharmacy personnel involvement in medication reconciliation in the clinical research setting. Pharmacists have the opportunity to ensure that IDs are accurately included in patient medication lists and to identify the use of potential protocol prohibited concomitant medications. (3)

2.3. Justyna Godyn at el., He presents current directions in the search for novel, potentially effective agents for the treatment of AD, as well as selected promising treatment strategies. These include agents acting upon the beta-amyloid, such as vaccines, antibodies and inhibitors or modulators of g- and b-secretase; agents directed against the tau protein as well as compounds acting as antagonists of neurotransmitter systems (serotoninergic 5-HT6 and histaminergic H3). Ongoing clinical trials with Ab antibodies (solanezumab, gantenerumab, crenezumab) seem to be promising, while vaccines against the tau protein (AADvac1 and ACI-35) are now in early-stage trials. Interesting results have also been achieved in trials involving small molecules such as inhibitors of b-secretase (MK-8931, E2609), a combination of 5-HT6 antagonist (idalopirdine) with donepezil, inhibition of advanced glycation end product receptors by azeliragon or modulation of the acetylcholine response of a-7 nicotinic acetylcholine receptors by encenicline. Development of new effective drugs acting upon the central nervous system is usually a difficult and time-consuming process, and in the case of AD to-date clinical trials have had a very high failure rate. Most phase II clinical trials ending with a positive outcome do not succeed in phase III, often due to serious adverse effects or lack of therapeutic efficacy. (4)

2.4. Sakshi K. LoyaShe at el., builds the article is to build up phase IV clinical studies in combination with preceding preclinical experiments to gain a better sense of the lengthy road a medicine takes—not only until it hits the market, but also afterward. Other objectives include demonstrating the relationship with various aspects of post-marketing research, investigating the present function of phase IV studies, and researching the extent to which the current situation of phase IV clinical trials satisfies needs. (8)

2.5. Venkataramana Kandi at el., in this review, he attempts to delineate the different types of clinical research and their implications. (10)

2.6. Hisham A. Badreldin at el., He reviews clinical pharmacy education and training, its historical evolution, the current practice model, the challenges, and future perspectives in Saudi Arabia. (12)

2.7. Sarah Ronan at el., estimate the cost, cost avoidance, and the net cost benefit ratio of MR provided by pharmacists. Study I: Of 128 patients who received the MR, 113 interventions were made. The estimated cost of providing the MR was €2559 (senior pharmacist). Using €1084 as the cost of an adverse drug event (ADE), the cost avoidance was calculated at €42,330. This led to a net cost benefit of €39,771 (senior pharmacist) which equated to a net cost benefit ratio of 16.5:1. Study II: The main themes were (i) perceptions of pharmacy services, (ii) the role of the pharmacist—past, present and future, and (iii) teamwork and communication. Nurses expressed a desire to have more pharmacists present on the wards. (44)

2.8. Noor us Sabah at el., She concluded that the characteristics of a pharmacist's interactions with other health care teams and Expertise in analytical, pharmacological, and pharmacologic terminology, pharmacovigilance, honesty in documentation, etc. will Impact physician-pharmacist collaboration and improve patient care and patient requirements in trials, And also enhance the clinical research study outcomes. The role of clinical pharmacists is diverse in the clinical research industry, they can work as clinical trial assistants, clinical research coordinators, or clinical research associates, and thus, can also streamline the activities of clinical trials ensuring that all the trials procedures are followed according to ICH-GCP guidelines, standard operating procedures, and regulatory requirements. (33)

3. METHODOLOGY
(Phases of clinical trials)

3.1. Clinical trials

Any investigation in human subjects intended to discover or verify the clinical, pharmacological, and/or other pharmacodynamics effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to study the absorption, distribution, metabolism, and excretion of an investigational product(s) with the object of determining its safety and/or efficacy. **[34]** Clinical trials are critical for drug development because new medications and/or novel therapy procedures must be evaluated on humans to ensure their safety and efficacy in real-world patient situations. They normally progress through multiple separate phases (from I to IV) of varying duration, with the goal of meeting predefined targets in order to gain access to the pharmaceutical market. **[32]** A drug development process normally takes several years. Drugs are frequently tested in humans after undergoing laboratory testing. Human clinical trials are separated into series of phases:

a) Phase 0 trials
b) Phase I trials.
c) Phase II trials.
d) Phase III trials.
e) Phase IV trials.

Every phase of a clinical trial has a distinct goal. Generally, phase I studies demonstrate safety, phase II trials evaluate efficacy, phase III trials prove efficacy in comparison to existing standard treatment, and phase IV trials determine general hazards and benefits after the medicine has been licensed. **[50]** Since new potential drugs are tested for the first time on humans through phase 1 clinical trials, and because such studies are becoming increasingly complex in terms of study design, scientific and ethical features of phase 1 clinical trials are constantly revised to allow sponsors to be fully compliant with the current legislation. **[9]**

a) Phase 0 Trial

Conducting phase 0 studies is one technique for increasing clinical drug development efficiency and success. Phase 0 trials are first-in-human investigations that occur prior to typical phase I dose-escalation drug safety and tolerability assessment. Phase 0 trials, which entail smaller doses of the study substance provided for a limited duration (about V7 days), can be done under the auspices of the US. **[39]** This guidance demands far less preclinical toxicological effort than normal IND phase 1 research. As a result, phase 0 investigations can be carried out while toxicological studies are being completed in preparation for submitting a normal IND, and they will not 5 delay the time until the phase 1 study can begin. Phase 0 trials bridge the gap between the traditional preclinical and clinical testing phases, allowing researchers to develop a better understanding of

variables such as pharmacokinetics, pharmacodynamics, and target localization of a new compound, or a series of related compounds before undertaking phase 1 trials. **[34]** Exploratory IND studies (also known as Phase 0 studies) are undertaken early in the clinical phase, with limited human exposure and no therapeutic or diagnostic goal. Doses are sub therapeutic, and patients are observed by a clinical researcher. The trial includes approximately ten participants. **[38 book]**

b) Phase I Trial

A phase I trial seeks to provide early indicators of a drug's pharmacological activities, safety, and side effects. The medicine will be administered to humans for the first time during phase I trials, which include a small number of healthy individuals. **[50]** Phase I studies are exploratory first-in-human or early phase trials designed to assess the safety and tolerability of a new drug or vaccine in a small group of people (usually healthy volunteers, but in some therapeutic areas, such as cancer, participants are patients) and to determine the maximum tolerated dose (MTD).Phase I studies assist in determining the appropriate dose and frequency that are both safe and necessary to produce an effect. **[38book]** Phase 1 clinical trials are crucial to the development of novel cancer therapies. These trials are the first to test an experimental agent in humans and serve as a transition point from years of laboratory research to clinical use. The primary goals of phase 1 are to describe the agent's toxicity profile and to select a dose and schedule suitable for phase 2 testing. **[46]** Clinical researchers typically oversee trials involving 20 to 100 people. **[38]** Phase 1 trials now attempt to provide credible proof of clinical action in order to lead to therapeutic approval via the Accelerated Approval method or Breakthrough Therapy designation in circumstances when tumors are rare, the prognosis is bad, and there is an unmet need. As a result, early Phase 1 trials have expanded in scope, size, and accessibility. **[47]** Traditionally, phase I clinical trials involve patients with all disease types who have exhausted all available anti-cancer treatment options. The introduction of quick, low-cost genomic testing provides an opportunity to develop biomarker-driven trials. **[48]**

c) Phase II Trial

A phase II cancer treatment study is an uncontrolled experiment designed to provide an initial estimate of the medication's anticancer activity. The proportion of patients whose tumors shrink by at least 50% is the primary goal of most phase II trials, although the durability of such responses is also of relevance. **[51]** Phase II study designs are presented that assess both clinical response and toxicity, and are structurally comparable to Simon's two-stage designs. **[17]** Phase II trials with CAD106 did not result in adverse effects observed in the case of AN-1792, and approximately 75% of patients reacted with appropriate antibody production. **[4]** These studies are conducted on bigger groups (100 to 300 people) and are intended to test the drug's efficacy and to continue safety assessments. **[50]** Phase II trials, sometimes known as "therapeutic exploratory" trials, are typically larger than phase I studies and involve a modest number of volunteers with the disease of interest. **[53]** Most phase II clinical studies with a positive outcome fail in phase III, generally due to substantial adverse effects or a lack of therapeutic efficacy. **[4]** The goals of this single-agent phase II study were to: (1) determine the objective response rate to gemcitabine given weekly at a starting dose of 800 mg/m2 for 3 weeks every 4 weeks in patients with advanced or metastatic breast cancer who had received up to one prior chemotherapy regimen that included adjuvant therapy, and (2) determine the tolerability profile of gemcitabine in these patients. **[18]**

d) Phase III trial

This international, multi-center, prospective phase III study began in 2002 and is planned to end in the middle of 2005, albeit the accrual appears to be constrained by the prevalence of pemetrexed trials. **[26]** The most critical factor to consider while creating a seamless study is the primary endpoint that will serve as the basis for registration. Endpoints in phase III must be fully understood and acceptable to health authorities in order to offer a basis for approval. **[37]** The trials may be challenging to design and conduct. Large groups (100 to 3000 patients) are recruited, and trial methods include randomized controlled trials (parallel design), uncontrolled trials (single therapy), historical controls, non-randomized concurrent trials, factorial designs, and group sequential designs. Patients are observed by the clinical researcher and their personal physician. [38] Furthermore, the investment required for one successful therapeutic launch increased by more than 55% in less than a decade, owing in large part to the investment required to take a drug from the laboratory and carry it through the clinical phase I to III trials required for filing and drug launch: the steps between discovery and approval known as the "Critical Path". **[6]** A phase III trial (also known as a "therapeutic confirmatory," "comparative efficacy," or "pivotal trial") may be conducted if preceding studies have demonstrated drug safety and potential efficacy. However, because phase III trials are typically limited to 300 to 3000 participants, they have the statistical power to establish an adverse event rate of at least one in every 100 people. **[53]**

e) Phase IV trials

Phase IV is known as the post-approval or post-marketing surveillance phase. **[8]** Approximately 20% of medications had new black box warnings after commercialization, and 4% were eventually discontinued for safety concerns The Food and medicine Administration Amendment Act (FDAAA) 7 authorized the Food and Drug Administration to conduct post marketing clinical trials to address safety concerns about a specific medicine in 2007. In contrast to premarketing phase I-III trials, phase IV studies assess drug safety in a real-world situation, which may give evidence to ensure or further refine the safety of approved drugs. **[27]** However, little is known about the characteristics of current phase IV clinical trials and whether these investigations are of sufficient quality to increase medical knowledge in pharmacovigilance. **[22]** Phase IV trials are observational in nature, with a focus on safety and gathering as much valid information as possible about the drug's growing benefit-risk profile. **[41]** The FDA decides whether a therapy can be granted an indication and sold after an exhaustive review, which frequently includes a proposal from an external committee. Following final approval, the medicine can be explored further in phase IV trials, which will assess its safety and effectiveness in the indicated population. **[54]** These Phase IV studies consist of "all studies (other than routine surveillance) performed after drug approval and related to the approved indication". These are post-market surveillance studies. [38] The goals of Phase IV activities are to expand the efficacy and safety database, collect comparison data for other treatment modalities (e.g., comparator medications), and build an outcome assessment database to provide a clinical foundation for health economics and HTA. **[41]** Phase IV clinical trials take place after a medicine or medical device has been approved by the FDA and is on the market. These trials, also known as post-marketing surveillance studies, are aimed to evaluate the safety and efficacy of the medicine or device in a larger population and for a longer length of time than was possible in pre-marketing clinical trials. **[8]**

3.2. Role of pharmacist in clinical trials

Pharmacists may provide expert advice and lead efforts to incorporate information technology into the medication-use process for experimental medications. The prescribing stage of the drug usage process is generally acknowledged as the most significant contributor to medication mistakes. **[57]** Pharmacists have been demonstrated to reduce medication inconsistencies in patient health records, making them excellent healthcare practitioners for reconciling the subject's medication history with protocol criteria in a clinical research context. **[3]** A clinical pharmacist may offer the patient with statistics on ongoing therapy in order to ensure drug supply, medication adherence aids, communication of unique issues, accurate dose monitoring, and minimal disruption. Furthermore, it can provide information on the patient's current clinical status as well as educate him or her on the safe and effective use of medications, so improving his or her treatment outcomes. **[33]** Responsibilities of pharmacists in relation to the "investigational medicinal product": The investigator is responsible for reporting the investigational medicinal product at the clinical trial location. Where permissible or required, the researcher may delegate some or all of his or her reporting responsibilities to the pharmacist or another authorized person under the researcher's supervision. The researcher, a pharmacist, or another person designated by the researcher must keep records of the medicinal supplies received at the venue, an inventory of the products at the center, the quantities used by each participant, and the amounts returned to the sponsor. **[11]** Pharmacists are increasingly involved in providing patient and population-based services. Growing data supports the effectiveness of these services in improving economic, clinical, and humanistic results in a variety of situations and care settings. **[20]**

3.3. Impact of clinical studies in drug development

For any pharmaceutical business or academic institution, progressing a therapeutic candidate to phase I clinical trials following extensive preclinical optimization is a significant achievement. However, nine out of ten medication candidates that enter clinical research fail during phase I, II, and III clinical trials and drug approval. **[21]** It is also worth noting that the 90% failure rate applies only to therapeutic candidates who have reached to phase I clinical trials and does not include those in the preclinical stages. If drug candidates in the preclinical stage are included, the failure rate of drug discovery/development exceeds 90%. **[1]**

3.4. Ethical consideration

The word "ethics" comes from the Greek word ethos, which meaning custom or character. Ethics always states, "Not I, but thou." Swami Vivekananda's phrase, "Not self, but non-self," serves as its motto. Human research began in the 1700s, when Edward Jenner tested a smallpox vaccine on his own son and neighboring youngsters. In the 1900s, Walter Reed's attempts to develop a yellow fever vaccine included evidence of free assent. In 1966, Henry K. Beecher presented in the New England Journal of Medicine twenty-two cases of unethical activities in clinical research, which sparked public indignation and interest among researchers in improving ethical methods in human research. **[55]** Under its umbrella, clinical research ensures that the study is carried out in accordance with the principles and norms established by local, national, and international agencies such as the Institutional Ethics Committee (IEC) and the International Council for Harmonization (ICH). Because clinical research is conducted on humans, ethical considerations such as the preservation of rights, safety, well-being, autonomy, and the right to remuneration of study participants become more important. **[23]** The ethical standards set in various codes and regulations are insufficient to address some of the ethical issues raised by clinical studies. We use this strategy to answer two questions: (I) is it ethical to recruit participants for a randomized clinical trial (RCT) solely from Veterans Administration (VA) hospitals? (2) Is it necessary to reveal in an RCT that therapy will be selected by chance? [36] Ethical approval was acquired from the School of Pharmacy's Ethical Review Committee at the University of Gondar, and each responder provided signed written informed permission. **[52]**

3.5. Challenges and limitations

The obstacles identified by the majority of respondents stem from the pharmacist, other health practitioners, hospital management and infrastructure, academic policies, and the availability of work instructions. Pharmacist-related issues include insufficient service advertising, a lack of service continuity, inadequate DIC service, and clinical pharmacists' lack of dedication, communication, and confidence. **[52]**

3.6. Multiplicity of clinical practice guidelines

A healthcare worker who employs suggestions for the management of a clinical or health condition generally encounters different sources of information, including clinical practice guidelines developed by government agencies, local scientific associations, or recognized international institutions (such as the American Heart Association and the National Institute for Health and Care Excellence (NICE), among others). However, suggestions can differ amongst clinical practice guidelines, and the professional may be unsure which guideline to employ for his or her clinical judgment. In general, professionals can select those with greater methodological rigor, but these regulations may not include information relevant to the local environment. This issue will be remedied if high-quality clinical practice standards are developed to adapt to the local environment of healthcare professionals and their patients. **[40]**

3.7. Multimorbidity

Most clinical practice guidelines focus on a single problem (e.g., diabetes, coronary heart disease, depression). However, patients frequently have multiple illnesses at the same time, known as multimorbidity, which is not typically covered in clinical practice guidelines and may necessitate the application of recommendations from multiple standards concurrently. Recent findings indicate that the simultaneous use of independent clinical practice guidelines in patients with multimorbidity may be associated with substantial adverse responses due to drug-drug or drug-disease interactions. Because of this issue, the field of producing clinical practice recommendations allows to address multimorbidity when assessing the treatment burden, the selection of therapies with greatest effectiveness, and their potential interactions, among others. **[25]**

4. Future prospective of clinical study

1) Decentralized Clinical Trials (DCTs)

DCTs leverage digital technologies to conduct studies remotely, improving patient recruitment and retention. [58]

2) Artificial Intelligence and Machine Learning

AI and machine learning are being used for patient selection, data analysis, and predicting outcomes. [59]

3) **Patient-Centric Approaches**
Focusing on patient experience and involvement in study design can enhance adherence and data quality. **[60]**

4) **Wearable Technology and Remote Monitoring**
Wearables allow for continuous monitoring of patient health data, providing richer datasets for analysis. **[61]**

5) **Regulatory Evolution**
Regulatory agencies are adapting to new technologies and methodologies, promoting innovation in clinical trial designs. **[62]**

6) Real-World Evidence (RWE)
Incorporating RWE can enhance understanding of treatment effects outside controlled settings. [63]

7) Adaptive Trial Designs
These allow for modifications to trial protocols based on interim results, increasing efficiency and ethical standards. [64]

5. Case studies and examples

➢ Clinical Trial of a New Antihypertensive Drug

❖ **Study Title:** Efficacy and Safety of Drug X in Patients with Stage 2 Hypertension
❖ **Objective:** To evaluate the efficacy and safety of Drug X compared to a placebo in lowering blood pressure in patients with stage 2 hypertension.

❖ **Study Design:**

- **Type:** Randomized, double-blind, placebo-controlled trial
- **Duration:** 12 weeks
- **Participants:** 300 patients aged 40-70 years with stage 2 hypertension (systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg)
- **Intervention:** Drug X (50 mg/day) vs. placebo
- **Endpoints:** Primary endpoint - Change in systolic blood pressure; Secondary endpoints - Change in diastolic blood pressure, quality of life assessment, and adverse events.

6. Methods:

Recruitment: Patients were recruited from multiple clinical sites. Eligibility was confirmed through screening visits.
Randomization: Participants were randomly assigned to either the Drug X group or the placebo group using a computer-generated randomization list.
Blinding: Both participants and investigators were blinded to treatment allocation to minimize bias.
Data Collection: Blood pressure measurements were taken at baseline, 6 weeks, and 12 weeks. Quality of life was assessed using the EQ-5D scale.

7. Results:

Primary Endpoint: The Drug X group showed a statistically significant reduction in systolic blood pressure compared to placebo (mean reduction of 15 mmHg vs. 3 mmHg, $p < 0.001$).

Secondary Endpoints: Similar results were observed for diastolic blood pressure. Quality of life scores improved in the Drug X group ($p < 0.05$).
Safety: Adverse events were similar between the two groups, with Drug X showing a favorable safety profile.
Conclusion: Drug X is effective in reducing blood pressure in patients with stage 2 hypertension and demonstrates an acceptable safety profile. **[65, 66, 67, 68, 69, 70]**

8. Result

Clinical trials produce data that supports the safety and efficacy of novel medications, which guides their approval and usage in practice. Pharmacists use study results to offer evidence-based recommendations, guaranteeing the best patient care and medication management. Results frequently show novel therapeutic uses or populations that can benefit from a medicine, broadening its clinical applications. Ongoing clinical trials help discover potential side effects and interactions, which contribute to post-marketing surveillance and patient safety. Clinical study results are critical for completing regulatory standards and accelerating the clearance process for new drugs. Clinical research allows pharmacists to expand their knowledge and skills, which helps to progress the profession.
Overall, the findings of clinical trials are critical for advancing pharmaceutical practice and improving patient outcomes.

9. Conclusion

Clinical trials are important in the field of pharmacy because they provide the evidence needed to assess the safety and efficacy of drugs. These studies help to inform medication development, guide clinical practice, and improve patient care by allowing pharmacists to make sound decisions based on reliable evidence. Furthermore, clinical research adds to the evolution of pharmacological knowledge by identifying new therapeutic applications and refining current medicines. As the healthcare landscape evolves, well-designed clinical studies will remain crucial to ensuring that patients receive high-quality, effective, and safe drugs.

10. References

1. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it?. Acta Pharmaceutica Sinica B. 2022 Jul 1;12(7):3049-62.
2. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2019. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2019 Jan 1;5:272-93.
3. Redic KA, Skyles A, Zaccardelli J. Potential role of a pharmacist to enhance medication-related aspects of clinical trials conducted in a dedicated clinical research unit. Contemporary Clinical Trials Communications. 2017 Jun 1;6:55-7.
4. Godyń J, Jończyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacological Reports. 2016 Feb 1;68(1):127-38.
5. Collier R. Legumes, lemons and streptomycin: a short history of the clinical trial.
6. LoRusso PM, Boerner SA, Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clinical Cancer Research. 2010 Mar 15;16(6):1710-8.
   Kandi V, Suvvari TK, Vadakedath S, Godishala V. Microbes, clinical trials, drug discovery, and vaccine development: the current perspectives. Borneo Journal of Pharmacy. 2021 Nov 30;4(4):311-23.
8. Loya SK, Baheti LD. A Comprehensive Review Clinical Trials: Phase IV.Ethics of phase IV oncology study. Reexamining the argument and data.
9. Kandi V, Vadakedath S. Clinical research: an overview of study types, designs, and their implications in the public health perspective. Am J Clin Med Res. 2021;9(2):36-42.
10. ATANASOV MP. *STUDY OF THE ROLE AND PARTICIPATION OF THE PHARMACIST IN CLINICAL TRIALS OF MEDICINAL PRODUCTS* (Doctoral dissertation, SOFIA UNIVERSITY" ST. KLIMENT OHRIDSKI).
11. Badreldin HA, Alosaimy S, Aljedai A. Clinical Pharmacy Practice in Saudi Arabia: Historical Evolution and Future Perspective Running title: Clinical Pharmacy Practice in Saudi Arabia.

12. Hawksworth GM, Chrystyn H. Clinical pharmacy in primary care. British journal of clinical pharmacology. 1998 Nov;46(5):415.
13. Bhattamisra SK, Banerjee P, Gupta P, Mayuren J, Patra S, Candasamy M. Artificial intelligence in pharmaceutical and healthcare research. Big Data and Cognitive Computing. 2023 Jan 11;7(1):10.
14. Vijayananthan A, Nawawi O. The importance of Good Clinical Practice guidelines and its role in clinical trials. Biomedical imaging and intervention journal. 2008 Jan;4(1).
15. Yiannopoulou KG, Anastasiou AI, Zachariou V, Pelidou SH. Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research. Biomedicines. 2019 Dec 9;7(4):97.
16. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics. 1995 Dec 1:1372-83.
17. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL. Advanced breast cancer: a phase II trial with gemcitabine. Journal of Clinical Oncology. 1995 Nov;13(11):2731-6.
18. Kandi V, Vadakedath S. Clinical trials and clinical research: a comprehensive review. Cureus. 2023 Feb;15(2).
19. Dammo N, Harpe SE. Characteristics of studies of pharmacist services registered in ClinicalTrials. gov. Journal of the American Pharmacists Association. 2020 Jul 1;60(4):609-17.
20. Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019 Jul 8;18(7):495-6.
21. Zhang X, Zhang Y, Ye X, Guo X, Zhang T, He J. Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials. gov registry. BMJ open. 2016 Nov 1;6(11):e010643.
22. Vohora D. Ethical considerations in clinical research. InPharmaceutical medicine and translational clinical research 2018 Jan 1 (pp. 265-283). Academic Press.
23. Bhatt A. Evolution of clinical research: a history before and beyond James Lind. Perspectives in clinical research. 2010 Jan 1;1(1):6-10.
24. Farmer C, Fenu E, O'Flynn N, Guthrie B. Clinical assessment and management of multimorbidity: summary of NICE guidance. Bmj. 2016 Sep 21;354.
25. Favaretto A. Overview on ongoing or planned clinical trials in Europe. Lung cancer. 2005 Jul 1;49:S117-21.
26. Glasser SP, Salas M, Delzell E. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. The Journal of Clinical Pharmacology. 2007 Sep;47(9):1074-86.
27. Gums JG. Changing the direction of clinical pharmacy outside the United States: time to step up. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2013 Feb;33(2):122-5.
28. Gupta SK. Role of Pharmacovigilance in ensuring safety of patients. Indian Journal of Medical Specialities. 2015 Apr 1;6(2):39-45.
29. Grimes DA, Schulz KF. An overview of clinical research: the lay of the land. The lancet. 2002 Jan 5;359(9300):57-61.
30. Thajer A, Sommersguter-Reichmann M, Löffler-Stastka H. Implementing a clinical research department to support pediatric studies: a SWOT Analysis. International Journal of Environmental Research and Public Health. 2020 Sep;17(17):6211.
31. Di Tonno D, Perlin C, Loiacono AC, Giordano L, Martena L, Lagravinese S, Rossi F, Marsigliante S, Maffia M, Falco A, Piscitelli P. Trends of Phase I Clinical Trials in the Latest Ten Years across Five European Countries. International Journal of Environmental Research and Public Health. 2022 Oct 28;19(21):14023.
32. Dunn SP, Birtcher KK, Beavers CJ, Baker WL, Brouse SD, Page RL, Bittner V, Walsh MN. The role of the clinical pharmacist in the care of patients with cardiovascular disease. Journal of the American College of Cardiology. 2015 Nov 10;66(19):2129-39.
33. Ingle PV, Patel RA, Patil PH, Surana SJ. Phase-0: a general overview. Indian Journal of Pharmacy Practice. 2013;6(3).
34. Cummings JL, Tong G, Ballard C. Treatment combinations for Alzheimer's disease: current and future pharmacotherapy options. Journal of Alzheimer's disease. 2019 Jan 1;67(3):779-94.

35. Mousavinejad S, Bazmi S, Rezaei-Tavirani M, Shamsi-Gooshki E, Enjoo SA, Kiani M. Ethical considerations in conducting clinical trials. International Journal of Medical Toxicology and Forensic Medicine. 2021;11(4):1-4.
36. Maca J, Dragalin V, Gallo P. Adaptive clinical trials: overview of phase III designs and challenges. Therapeutic Innovation & Regulatory Science. 2014 Jan;48(1):31-40.
37. Mahan VL. Clinical trial phases. International Journal of Clinical Medicine. 2014 Dec 29;5(21):1374-83.
38. Rossi A, Pilotto S, Carbognin L, Ferrara MG, Belluomini L, Daniele G, Bria E. Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. Journal of Molecular Pathology. 2021 Jun 23;2(3):207-22.
39. Kredo T, Bernhardsson S, Machingaidze S, Young T, Louw Q, Ochodo E, Grimmer K. Guide to clinical practice guidelines: the current state of play. International Journal for Quality in Health Care. 2016 Feb 1;28(1):122-8.
40. Prajapati V, Tripathy S, Dureja H. Product lifecycle management through patents and regulatory strategies. Journal of Medical Marketing. 2013 Aug;13(3):171-80.
41. Nikam S, Jambhulkar A, Kayande K, Ghule A, Inde A. Pharmacovigilance Safety Monitoring in Clinical Trials. Int. J. Pharm. Sci. Rev. Res. 2021;70:9-16.
42. Ise N, Takechi K, Miyamoto T, Ishizawa K, Yanagawa H. Pharmacy Students' Knowledge and Attitude toward Registration Trials and Clinical Research: A Survey in a Japanese University Hospital. Pharmacy. 2017 Dec 11;5(4):67.
43. Ronan S, Shannon N, Cooke K, McKeon T, Walsh EK, Kearney A, Sahm LJ. The role of the clinical pharmacist in an Irish university teaching hospital: a mixed-methods study. Pharmacy. 2020 Jan 30;8(1):14.
44. Althomali A, Altowairqi A, Alghamdi A, Alotaibi M, Althubaiti A, Alqurashi A, Harbi AA, Algarni MA, Haseeb A, Elnaem MH, Alsenani F. Impact of clinical pharmacist intervention on clinical outcomes in the critical care unit, Taif City, Saudi Arabia: a retrospective study. Pharmacy. 2022 Aug 31;10(5):108.
45. Roberts TG, Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, Gazelle GS, Finkelstein SN, Clark JW. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. Jama. 2004 Nov 3;292(17):2130-40.
46. Iasonos A, O'Quigley J. Randomised Phase 1 clinical trials in oncology. British Journal of Cancer. 2021 Sep 28;125(7):920-6.
47. Cook N, Hansen AR, Siu LL, Razak AR. Early phase clinical trials to identify optimal dosing and safety. Molecular Oncology. 2015 May 1;9(5):997-1007.
48. Kumar MR, Bodhanapu S, Mani TT, Phaneendra P, Rahiman OF. Pharmacovigilance and its importance in drug regulation: An Overview. Der Pharm. Lett. 2011;3:165-9.
49. Mahan VL. Clinical trial phases. International Journal of Clinical Medicine. 2014 Dec 29;5(21):1374-83.
50. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled clinical trials. 1989 Mar 1;10(1):1-0.
51. Tegegn HG, Abdela OA, Mekuria AB, Bhagavathula AS, Ayele AA. Challenges and opportunities of clinical pharmacy services in Ethiopia: a qualitative study from healthcare practitioners' perspective. Pharmacy Practice (Granada). 2018 Mar;16(1).
52. Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. Postgraduate medicine. 2011 Sep 1;123(5):194-204.
53. Viktil KK, Blix HS. The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic & clinical pharmacology & toxicology. 2008 Mar;102(3):275-80.
54. McCarthy P, Peach RK. Ethical Considerations in Clinical Research. Journal of the Academy of Rehabilitative Audiology. 1993;26:51-6.
55. Mahan VL. Clinical trial phases. International Journal of Clinical Medicine. 2014 Dec 29;5(21):1374-83.
56. Patel H, Gurumurthy P. Improving medication safety in oncology care: impact of clinical pharmacy interventions on optimizing patient safety. International Journal of Clinical Pharmacy. 2019 Aug 1;41(4):981-92.

57. Dimitrova M, Hristov R, Djemadan A, Gaytandzieva I. Decentralized Clinical Trials–Current Environment, Potential Barriers and Facilitators for Implementation and Risk Mitigation: A Review of the Literature. Acta Medica Bulgarica. 2023 Dec 15;50(4):73-8.
58. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, Cui C, Corrado G, Thrun S, Dean J. A guide to deep learning in healthcare. Nature medicine. 2019 Jan;25(1):24-9.
59. Patient and public involvement in clinical trials
60. Izmailova ES, Wagner JA, Perakslis ED. Wearable devices in clinical trials: hype and hypothesis. Clinical Pharmacology & Therapeutics. 2018 Jul;104(1):42-52.
61. Razavi M, Glasziou P, Klocksieben FA, Ioannidis JP, Chalmers I, Djulbegovic B. US Food and Drug Administration approvals of drugs and devices based on nonrandomized clinical trials: a systematic review and meta-analysis. JAMA Network Open. 2019 Sep 4;2(9):e1911111-.
62. Epstein RS, Sidorov J, Lehner JP, Salimi T. Integrating scientific and real-world evidence within and beyond the drug development process. Journal of Comparative Effectiveness Research. 2012 Jan;1(1s):9-13.
63. Berry DA. Bayesian clinical trials. Nature reviews Drug discovery. 2006 Jan 1;5(1):27-36.
64. Piantadosi S. Clinical trials: a methodologic perspective. John Wiley & Sons; 2024 Apr 30.
65. Chow SC, Liu JP. Design and analysis of clinical trials: concepts and methodologies. John Wiley & Sons; 2008 Dec 4.
66. Whelton PK, Carey RM, Aronow WS. Acc/aha/aapa/abc/acpm/ags/APhA/ASH/ASPC/nma/pcna guideline for the prevention, Detection, evaluation, and management of high blood pressure in adults: a Report of the American College of Cardiology/American heart Association. Task force on clinical practice guidelines//J. Am. Coll. Cardiol.-2017.-Nov 13. Почки. 2018;7(1):68-74.
67. Senn SS. Cross-over trials in clinical research. John Wiley & Sons; 2002 Aug 30.
68. Mondal H, Mondal S. A Brief Review on Good Clinical Practice and its Training Methods. Indian Dermatology Online Journal. 2024 May 1;15(3):377-82.
69. Group TE. EuroQol-a new facility for the measurement of health-related quality of life. Health policy. 1990 Dec 1;16(3):199-208.